Research
Metabolic adaptation
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.
Health systems should prepare for a significant increase in MASLD cases.
StrongSupportsmedium confidence
The model predicted a steady increase in the prevalence of MASLD from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.
Why this rating
Based on a decision analytical modeling study design.
Source
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
Phuc Le et al. · JAMA Network Open · 2025
other · n=2821624Cited 165×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →